

# Vulinacimab Biosimilar - Research Grade

**Product Code:** ICH5994

**More Information**

**Species Reactivity:** Human

**Target:** KDR $\alpha$

**Concentration:** 5mg/ml

**Isotype:** IgG1 - kappa

**Host:** CHO Cells

**product name H2:** Vulinacimab Biosimilar - Research Grade

**Sequence:** <https://www.imgt.org/mAb-DB/>

**Buffer:** ICH3002

**UniProt:** P35968

**Shipping Conditions:** Blue ice

**background:** VEGFR-2 (KDR) is the principal receptor mediating VEGF-driven angiogenesis and a central target across cancer and vascular biology research. This recombinant human IgG1 monoclonal is an unconjugated, non-therapeutic analog of vulinacimab directed against KDR and is supplied for research use only (RUO). It is purified to a low-endotoxin standard appropriate for in vivo studies and produced in scalable milligram to gram quantities for bulk and high-throughput laboratories. Applications include receptor-blocking and binding assays, in vitro angiogenesis and VEGF-signaling screens, control work, and preclinical tumor and vascular models.

**Purification Method:** This monoclonal antibody was purified using Protein A

**Formulation:** Sterile, preservative-free, solution in PBS. BSA and Azide free.

**Purity:** >90% by SDS-PAGE



**Endotoxin:**  $\leq 1.0$  EU/mg as determined by the LAL method

**Storage:** This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

**Applications:** Functional Assays

**Application Notes:** This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

**Use:** Products are for research use only. Not for use in diagnostic or therapeutic procedures.

**Delivery Time:** 3-4 weeks